SOMERSET, N.J., Nov. 17, 2008 (GLOBE NEWSWIRE) -- inVentiv Health (Nasdaq:VTIV) is pleased to announce that GeneraMedix Inc., a pharmaceutical company that develops, markets and distributes generic injectable products, has selected inVentiv to deliver integrated strategic marketing and branding services for the corporation. inVentiv will provide a wide range of services for GeneraMedix's new specialty Epoprostenol therapy, which is used for treatment of hypertension.
The following inVentiv companies will work in collaboration to deliver an integrated branding and marketing program for GeneraMedix:
* Stonefly Communications Group, a patient-focused, insights-driven advertising agency, will provide brand management, marketing and strategic counseling; * Strategyx, a leading consulting firm specializing in channel marketing, product launch strategy and organization design, will be responsible for a strategic pricing study and market assessment; and, * Addison Whitney, a leading brand development and identity consultancy, will take on naming efforts for the product.
"GeneraMedix Inc. has built a solid reputation in the generic injectable market and now has an opportunity to expand its business with the launch of a specialty brand," said John Racik, President and CEO of Stonefly Communications Group. "We're excited to be helping them build a deeper understanding of the market landscape and their prospective customers, and to develop a strong brand that leverages those insights."
GeneraMedix's Epoprostenol for Injection 1.5 mg therapy is indicated for the long-term treatment of primary pulmonary hypertension and pulmonary hypertension associated with NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
"We are thrilled to be working with Stonefly and its collaborative culture of bringing in other inVentiv Health resources and expertise," said Robin Smith Hoke, President, Commercial Operations at GeneraMedix. "inVentiv Health's extensive branding and communications experience, deep knowledge of specialty marketing, and unique integrated approach make them an ideal strategic partner."
About GeneraMedix
GeneraMedix Inc. is a privately-held pharmaceutical company offering high quality generic injectable products to the U.S. hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July of 2004. Additional information is available on the company's website at www.generamedix.com
About inVentiv Health
inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.
The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.